自成立以来，公司凭借创新成果和国际化的运营模式在众多生物制药公司中脱颖而出，获得了富达、礼来亚洲基金、美国资本集团、君联资本、淡马锡、国投创新等全球多家知名创投基金资本支持。已建立起了一条包括多个单克隆抗体新药品种的产品链，覆盖肿瘤、眼底病、自身免疫疾病、心血管病等四大疾病领域，其中多个品种入选国家“重大新药创制”专项，7个品种进入临床研究，多个品种进入临床III期研究。
目前，公司按照CFDA、美国FDA和欧盟EMA的GMP标准建成高端生物药产业化基地。产业化生产线已通过合作方国际制药集团产业化生产要求的GMP审计。已组建了一支具有国际先进水平的高端生物药开发、产业化人才团队，多位海归专家。公司立足自主创新的产品与美国礼来制药集团达成了两次总金额超过15亿美元的全面战略合作。
开发出老百姓用得起的高质量生物药，是我们的理想和目标。
Since its inception, the company has stood out among many biopharmaceutical companies with its innovative achievements and international operation model, and has won many well-known global names such as Fidelity, Eli Lilly Asia Fund, American Capital Group, Junlian Capital, Temasek, and SDIC Innovation. Venture capital fund
Capital support. A product chain consisting of 17 new monoclonal antibody varieties has been established, covering four major disease areas including tumor, fundus disease, autoimmune disease and cardiovascular disease. Two of them have been selected into the national “Major New Drug Creation” project. EntryIn clinical studies, 4 breeds entered the clinical phase III study.
